News
When childhood becomes content, the consequences go far beyond the screen. Explore the hidden psychological costs of growing ...
The phase 3 POIESIS trial is set to investigate navtemadlin as an add-on therapy to Jakafi in patients with JAK inhibitor-naive myelofibrosis.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results